235 related articles for article (PubMed ID: 27626683)
1. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
Yoshioka Y; Suzuki T; Matsuo Y; Nakakido M; Tsurita G; Simone C; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Oncotarget; 2016 Nov; 7(46):75023-75037. PubMed ID: 27626683
[TBL] [Abstract][Full Text] [Related]
2. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
[TBL] [Abstract][Full Text] [Related]
3. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
5. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
[TBL] [Abstract][Full Text] [Related]
6. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.
Van Aller GS; Reynoird N; Barbash O; Huddleston M; Liu S; Zmoos AF; McDevitt P; Sinnamon R; Le B; Mas G; Annan R; Sage J; Garcia BA; Tummino PJ; Gozani O; Kruger RG
Epigenetics; 2012 Apr; 7(4):340-3. PubMed ID: 22419068
[TBL] [Abstract][Full Text] [Related]
7. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
Nakakido M; Deng Z; Suzuki T; Dohmae N; Nakamura Y; Hamamoto R
Neoplasia; 2015 Apr; 17(4):367-73. PubMed ID: 25925379
[TBL] [Abstract][Full Text] [Related]
9. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
Landgraf KE; Pilling C; Falke JJ
Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
12. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
13. A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability.
Estève PO; Chang Y; Samaranayake M; Upadhyay AK; Horton JR; Feehery GR; Cheng X; Pradhan S
Nat Struct Mol Biol; 2011 Jan; 18(1):42-8. PubMed ID: 21151116
[TBL] [Abstract][Full Text] [Related]
14. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
16. Fine-tuning AKT kinase activity through direct lysine methylation.
Guo J; Wei W
Cell Cycle; 2019 May; 18(9):917-922. PubMed ID: 31050579
[TBL] [Abstract][Full Text] [Related]
17. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
18. Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis.
Chu N; Salguero AL; Liu AZ; Chen Z; Dempsey DR; Ficarro SB; Alexander WM; Marto JA; Li Y; Amzel LM; Gabelli SB; Cole PA
Cell; 2018 Aug; 174(4):897-907.e14. PubMed ID: 30078705
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
20. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Kim H; Heo K; Kim JH; Kim K; Choi J; An W
J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]